Page 232 - Read Online
P. 232

Page 8 of 9                                                Giorgio et al. Hepatoma Res 2019;5:20  I  http://dx.doi.org/10.20517/2394-5079.2019.05

               2.   El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United
                   States: an update. Ann Intern Med 2003;139:817-23.
               3.   McGlynn  KA,  London  WT.  Epidemiology  and  natural  history  of  hepatocellular  carcinoma.  Best  Pract  Res  Clin  Gastroenterol
                   2005;19:3-23.
               4.   Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis
                   2008;29:1299-305.
               5.   Ho DW, Lo RC, Chan LK, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Cancer 2016;5:290-302.
               6.   Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular
                   carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373-82.
               7.   Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized
                   hepatocellular  carcinomas:  a  retrospective  and  nationwide  survey  in  Japan.  The  Liver  Cancer  Study  Group  of  Japan.  Hepatology
                   2000;32:1224-9.
               8.   Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular
                   carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
               9.   Korean Liver Cancer Study Group (KLCSG) and National Cancer Center, Korea (NCC). 2014 KLCSG-NCC Korea practice guideline
                   for the management of hepatocellular carcinoma. Gut Liver 2015;9:267-317.
               10.  Julie  K.  Heimbach,  Laura  M.  Kulik,  Richard  S.  Finn,Claud.  AASLD  guidelines  for  the  treatment  of  hepatocellular  carcinoma.
                   Hepatology 2018;67:358-80.
               11.  European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol
                   2018;69:182-236.
               12.  Italian Multi-Society reccomandations for the integrated management of Hepatocelluar Carcinoma. Published on line dec 22, 2106.
                   Available from: https://www.sirm.org/wp-content/uploads/2019/03/HCC.pdf. [Last accessed on 24 May 2019]
               13.  Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, et al. Guidelines and good clinical practice recommendations for contrast
                   enhanced  ultrasound  (CEUS)  in  the  liver  -  update  2012:  a  WFUMB-EFSUMB  initiative  in  cooperation  with  representatives  of
                   AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013;39:187-210.
               14.  Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and
                   spread: key pathologic and imaging aspects. Radiology 2014;272:635-54.
               15.  International  Consensus  Group  for  Hepatocellular  Neoplasia.  Pathologic  diagnosis  of  early  hepatocellular  carcinoma:  a  report  of
                   theinternational consensus group for hepatocellular neoplasia. Hepatology2009;49:658-64.
               16.  Quaia E, Calliada F, Bertolotto M, Rossi S, Garioni L, et al. Characterization of focal liver lesions with contrast-specific US modes and
                   a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 2004;232:420-30.
               17.  Salvatore V, Gianstefani A, Negrini G, Allegretti G, Galassi M, et al. Imaging diagnosis of hepatocellular carcinoma: recent advances
                   of contrast-enhanced ultrasonography with SonoVue®. Liver Cancer 2016;5:55-66.
               18.  Giorgio A, Ferraioli G, Tarantino L, de Stefano G, Scala V, et al. Contrast-enhanced sonographic appearance of hepatocellular carcinoma
                   in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance. AJR Am J Roentgenol 2004;183:1319-26.
               19.  Giorgio A, De Stefano G, Coppola C, Ferraioli G, Esposito V, et al. Contrast-enhanced sonography in the characterization of small
                   hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer
                   Res 2007;27:4263-9.
               20.  Quaia E, Lorusso A, Grisi G, Stacul F, Cova MA. The role of CEUS in the characterization of hepatocellular nodules detected during
                   the US surveillance program--current practices in Europe. Ultraschall Med 2012;33 Suppl 1:S48-56.
               21.  Dong Y, Mao F, Cao J, Fan P, Wang WP. Characterization of focal liver lesions indistinctive on b mode ultrasound: benefits of contrast-
                   enhanced ultrasound. Biomed Res Int 2017;2017:8970156.
               22.  Dong Y, Wang WP, Mao F, Dietrich C. Contrast-enhanced ultrasound features of hepatocellular carcinoma not detected during the
                   screening procedure. Z Gastroenterol 2017;55:748-53.
               23.  Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.
                   Hepatobiliary Surg Nutr 2017;6:387-96.
               24.  Kudo M, Matsui O, Izumi N, Iijima HD, Kadoya M, et al. JSH consensus-based clinical practice guidelines for the management of
                   hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer 2014;3:458-68.
               25.  Vilana R, Forner A, Bianchi L, García-Criado A, Rimola J, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may
                   display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010;51:2020-9.
               26.  Wildner D, Bernatik T, Greis C, Seitz K, Neurath MF, et al. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular
                   carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med 2015;36:132-9.
               27.  de Sio I, Iadevaia MD, Vitale LM, Niosi M, Del Prete A, et al. Optimized contrast-enhanced ultrasonography for characterization of
                   focal liver lesions in cirrhosis: a single-center retrospective study. United European Gastroenterol J 2014;2:279-87.
               28.  Giorgio A, Calisti G, Giorgio V. CEUS and HCC: are the 2008 EFSUMB guidelines still valid or has their wash-out already started?
                   Ultraschall Med 2011;32:315-6.
               29.  Giorgio A, Montesarchio L, Giorgio V. Misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast-enhanced ultrasound:
                   a real new clinical entity or just an exaggerated fear? Liver Int 2013;33:1608.
               30.  Giorgio A. Diagnostic algorithm of hepatocellular carcinoma on cirrhosis: CEUS or no CEUS, that is the problem. Dig Liver Dis
                   2011;43:499.
   227   228   229   230   231   232   233   234   235   236   237